Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19

IMPORTANCE: Protein recombinant vaccine NVX-CoV2373 (Novavax) against COVID-19 was authorized for its use in adults in late 2021, but evidence on its estimated effectiveness in a general population is lacking. OBJECTIVE: To estimate vaccine effectiveness of a primary cycle with NVX-CoV2373 against S...

Descripción completa

Detalles Bibliográficos
Autores principales: Mateo-Urdiales, Alberto, Sacco, Chiara, Petrone, Daniele, Bella, Antonino, Riccardo, Flavia, Del Manso, Martina, Bressi, Marco, Siddu, Andrea, Brusaferro, Silvio, Palamara, Anna Teresa, Rezza, Giovanni, Pezzotti, Patrizio, Fabiani, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551773/
https://www.ncbi.nlm.nih.gov/pubmed/37792377
http://dx.doi.org/10.1001/jamanetworkopen.2023.36854

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551773/
https://www.ncbi.nlm.nih.gov/pubmed/37792377
http://dx.doi.org/10.1001/jamanetworkopen.2023.36854

Ejemplares similares